Vincent A. Jourdain

Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys

Laurent Grégoire, Vincent A. Jourdain, Matthew Townsend et al. · Parkinsonism & Related Disorders · 2013 · 72 citations

Medicine, Neuropharmacology, Neuroprotection +6

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia

Renata P. Lerner, Veronica Francardo, Koji Fujita et al. · Scientific Reports · 2017 · 44 citations · Full text

Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia

Vincent A. Jourdain, Chris C. Tang, Florian Holtbernd et al. · JCI Insight · 2016 · 37 citations · Full text

Health Economics and Surgical Treatment for Parkinson's Disease in a World Perspective: Results from an International Survey

Vincent A. Jourdain, Gastón Schechtmann · Stereotactic and Functional Neurosurgery · 2014 · 29 citations · Full text

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys

Nicolas Morin, Vincent A. Jourdain, Marc Morissette et al. · Neuropharmacology · 2014 · 28 citations

Basal Ganglia, Functional Selectivity, Medicine +11